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ABSTRACT 
 
Coronary artery bypass grafting (CABG) is pivotal in the contemporary management of complex 
coronary artery disease. Inter-patient variability to antiplatelet agents, however, harbors potential to 
compromise the revascularization benefit by increasing the incidence of adverse events. This study 
was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among 
aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-
resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus 
aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end-point was a composite outcome 
of all-cause death, non-fatal myocardial infarction, stroke or cardiovascular hospitalization assessed at 
6 months postoperatively. The primary end-point occurred in 6% assigned to dAPT, and 10% of 
patients randomized to aspirin-monotherapy (relative risk [RR] 0.61 [95% CI 0.25-1.51]; p=0.33). No 
significant treatment effect was noted in the occurrence of the safety endpoint. The total incidence of 
bleeding events was 25% and 19% in the dAPT and aspirin-monotherapy groups, respectively (RR 
1.34 [95% CI 0.80-2.23]; p=0.33). In the subgroup analysis dAPT led to lower rates of adverse events 
in patients with a body mass index >30 kg/m
2
 (0% vs. 18%, p<0.01) and those younger than 65 years 
(0% vs. 10%, p=0.02). In conclusion, the addition of clopidogrel in patients found to be aspirin 
resistant after CABG did not reduce the incidence of adverse events, nor did it increase the number of 
recorded bleeding events. Dual antiplatelet therapy did, however, lower the incidence of the primary 
end-point in obese patients and those younger than 65 years.  
 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01159639 
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INTRODUCTION 
 Coronary artery bypass grafting (CABG) remains the standard of care in the management of 
complex coronary artery disease.
1
 Improvements in postoperative outcomes rely both upon technical 
refinements of the procedure and optimization of medical management. The long-term benefits of 
CABG depend upon the durability of non-obstructed flow through bypass grafts. Inhibition of platelet 
aggregability plays a crucial role in improving graft patency. Aspirin is currently the most commonly 
employed antiplatelet agent after CABG.
2 
Dual anti-platelet therapy (dAPT) may improve venous graft 
patency
3
, but this benefit has not been reliably reproduced in a wider clinical arena.
4
 The combination 
of clopidogrel and aspirin results in cumulation of their individual antiaggregatory effects, since their 
individual mechanisms of antiplatelet activity differ.
5
 Dual platelet inhibition may be of particular 
importance in patients exhibiting single antiplatelet drug resistances.
6
 Defining the role of dAPT in the 
contemporary surgical practice is paramount before recommending it without reservations, however, 
as it may increase the incidence of bleeding.
7 
The incidence of low-response to aspirin is not uniform 
across the available spectrum of platelet function tests. It has been reported to range from 1 to 45%.
8
 
While clear outlines of this phenomenon remain to be defined, its adverse clinical impact has been 
validated.
9
 We hypothesized that augmentation of platelet inhibition with clopidogrel in patients with 
high postoperative on-aspirin platelet reactivity would lead to improvement in clinical outcomes. The 
convergence of the clinical impact of aspirin resistance with the beneficial effects of dAPT in other 
clinical scenarios was at the foundation of this trial’s design. This is, to the best of our knowledge, the 
first prospective randomized study that selectively implemented dAPT after CABG in patients with 
aggregometry-documented aspirin resistance. 
 
METHODS 
The study was conducted at the University Hospital Center Zagreb in Zagreb, Croatia. Patient 
enrolment started in June 2010 and was completed in February 2013. Details of the study design, 
eligibility and exclusion criteria have been published previously.
10
 Briefly, adult patients scheduled to 
undergo elective primary CABG were eligible for enrolment. Exclusion criteria included valvular 
pathology warranting surgical correction, off-pump CABG, requirement for dual antiplatelet 
 4
management, anticoagulation and critical condition prior to randomization. Patients undergoing 
CABG following a recent acute coronary syndrome were excluded, as there is data to suggest that they 
might benefit from dAPT.
11
 On postoperative day (POD) 4 patients underwent an aggregometry-based 
assessment of their on-aspirin platelet reactivity. Patients found to be aspirin-responders were 
excluded from further analysis, while aspirin-resistant patients were randomized into either the control 
or intervention groups.  
The trial was approved by the Ethics committee of the University Hospital Center Zagreb. 
Ethical standards in line with the Declaration of Helsinki were adhered to. Written informed consent 
was obtained from all patients prior to enrolment. 
Multiple electrode aggregometry (MEA) was used for quantifying platelet reactivity in the 
study cohort (Multiplate, Dynabyte, Munich, Germany). Platelet aggregation, as evaluated by MEA, is 
responsible for variability in sensor wire impedances. The numerical MEA output describes the 
electrical resistance between sensor wires, which is proportional to platelet adherence.
12
 Arachidonic 
acid (0.5 mM) and adenosine diphosphate (ADP, 6.4µM) were utilized as platelet agonists for 
conducting the ASPI and ADP tests, respectively.  
The ASPI test evaluates COX-1 dependent platelet aggregation, and is therefore a surrogate 
for aspirin responsiveness. While aspirin response is better described as a continuous variable, 
dichotomizing patients into “responders” and “non-responders” is commonly utilized for research 
purposes.
8
 Aspirin resistance in the present study was defined in line with previous reports stratifying 
individual patient responsiveness into quartiles.
13
 Patients were classified as aspirin-resistant if their 
ASPI test values exceeded the population’s 75
th
 percentile cut-off point (area under the curve 
(AUC)≥30).
13
 This definition was substantiated by data from multiple other sources.
14,15
  
Having met the inclusion criteria for aspirin resistance on POD 4, patients scheduled for isolated 
CABG were randomly allocated into either continuation on 300 mg of aspirin (control group), or 
enhancement of platelet inhibition with 75 mg of clopidogrel plus 300 mg of aspirin (dAPT group). 
Randomization software was used for patient allocation into the control or intervention arms.
10 
Preoperative platelet inhibition with aspirin was maintained up to the day of surgery. 
Conversely, patients receiving preoperative clopidogrel had the drug discontinued approximately 5 
 5
days prior to the surgical procedure. Tepid cardiopulmonary bypass (CPB) and cardioplegic arrest 
were used in all study patients. Myocardial preservation was based on a combination of antegrade and 
retrograde cardioplegia. Postoperatively, patients typically received a beta-blocker, hydroxy-methyl-
glutaryl-CoA reductase inhibitor, peptic ulcer prophylaxis and a diuretic. Angiotensin-converting-
enzyme inhibitors were administered selectively, and titrated to effect. Aspirin was typically 
administered within the first six hours of surgery. In aspirin non-responders, the postoperative anti-
platelet regime was then re-evaluated on POD 4 in line with the study protocol.  
The primary efficacy end-point was the incidence of major adverse cardiac and 
cerebrovascular events (MACCE) at 6-months. MACCE was a composite outcome including all-cause 
mortality, non-fatal myocardial infarction, cerebrovascular accident and cardiovascular 
rehospitalization. The secondary outcomes were bleeding events and individual MACCE components. 
We adhered to the Bleeding Academic Research Consortium (BARC) definitions in presenting the 
safety end-point data.
16
 The Joint European Society of Cardiology/American College of Cardiology 
Foundation/American Heart Association/World Heart Federation Task Force for the Redefinition of 
Myocardial Infarction (MI) was implemented in patients suspected to have ischemic myocardial 
injury.
16
 Patients with new focal neurologic deficits lasting more than 24 hours, or those having an 
acute cerebral lesion on an imaging study were considered to have had a stroke.
17 
The study was designed to analyze the incidence of MACCE at 6-months, on an intention-to-
treat basis, in aspirin-resistant patients randomized to either continue on aspirin monotherapy or 
receive dual inhibition of platelet aggregation. The sample size required to test the null hypothesis was 
determined by an exact binomial test power analysis.
18 
The minimum effect size was 10%. Accounting 
for an estimated 10% loss to follow-up, a total of 219 patients were required to test the null hypothesis 
with an α value of 0.05 and a power of 0.8. An additional per-protocol analysis of the safety end-point 
was performed in patients adhering to the study protocol. The continuous data were presented as mean 
values with their standard deviation. Categorical variables were presented as absolute numbers with 
percentages. The Mann-Whitney U test was used to analyze continuous data between the control and 
intervention groups. Comparisons between categorical variables were performed with Fisher’s exact 
test. Changes in platelet reactivity in response to surgery were evaluated with the Wilcoxon matched-
 6
pairs test. Relative risks were used as a measure of the association between the intervention and 
clinical outcomes. The respective 95% confidence intervals were provided. A two-tailed p value <0.05 
was considered to be statistically significant for all deployed calculations. Additional one-tailed P 
values were also obtained and provided for comparisons likely to result in one-directional 
relationships. The data were processed using the IBM SPSS Statistics software package (version 20.0; 
Somers, NY, USA) and Statpages.org. 
 
RESULTS 
During the recruitment period 2034 patients were screened for eligibility. A total of 224 
aspirin resistant CABG patients were randomly assigned to receive aspirin only (n=110) or aspirin 
plus clopidogrel (n=114). An overview of the patient enrolment and randomization is presented in 
Figure 1. The baseline patient demographic and clinical profiles were well balanced between the two 
groups (Table 1). Approximately three quarters of patients were male and the majority had three-
vessel disease, which is representative of the contemporary cardiac surgical practice. Beta-blockers 
were utilized more commonly in the dAPT group prior to surgery. The use of other preoperative 
medications, including anti-platelet agents, did not differ significantly between the groups (Table 1). 
Perioperative data are summarized in Table 2. Postoperative medication regimes did not differ 
between the groups with the notable exception of clopidogrel utilization, which was subject to the 
randomization protocol (Table 2).  
 There were no differences in preoperative platelet aggregability between the groups (Table 1). 
The ASPI test values evaluated on POD 4 were also comparable between the control and intervention 
groups (Table 2). Postoperative ASPI test values in both patient groups were well above the pre-
defined 30 AUC cut-off point discriminating between aspirin response and resistance. Analogously, 
the postoperative ADP test values did not differ between the groups (Table 2). We have, however, 
documented a significant post-procedural rise in platelet reactivity in comparison to the respective 
preoperative values. The ASPI test values across the entire cohort increased from 36±29 to 57±26 
AUC (p<0.001). This accelerated platelet aggregability was corroborated by an increase in the ADP 
values (preoperatively: 78±26; postoperatively: 96±33 AUC, p<0.001). Additional evidence for a 
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hypercoagulable state in the early postoperative period was found in the dynamics of fibrinogen levels. 
We documented a consistent and statistically significant increase in fibrinogen concentrations in 
response to the surgical procedure (4.1±1.3 vs. 6.8±1.4 g/L; p<0.001). The observed rise in platelet 
aggregability was seen in both groups, irrespective of the antiplatelet management strategy (Figure 2).  
 Six-month follow-up was completed in 107 (97%) and 112 (98%) patients in the aspirin 
monotherapy and dAPT groups, respectively. The study outcomes are summarized in Table 3. 
Freedom from MACCE at the completion of the follow-up period was 90% in the control group and 
94% in the dAPT group. The overall incidence of the primary end-point was not affected by the 
different anti-platelet management protocols (6% vs. 10%; relative risk [RR]: 0.61 [95% CI: 0.25 to 
1.51]; two-tailed p=0.33, one-tailed p=0.20). A non-significant 43% relative risk reduction in the 
composite endpoint of MI/stroke/cardiovascular death was observed with enhancement of platelet 
inhibition (two-tailed p=0.49, one-tailed p=0.34). The frequency of individual MACCE components 
was not affected by the anti-platelet management strategy (Table 3). The causes of death in the 4 
control group patients were stroke, sepsis, necrotizing tracheitis and trauma. Two patients in the dAPT 
group died during follow-up. One suffered a stroke that eventually led to his death, while the other 
died of intractable respiratory failure induced by pneumonia. 
An intention-to-treat analysis revealed no statistically significant differences in the incidence 
of bleeding events between the groups within any of the BARC strata (Table 3). A non-significant 
increase in the frequency of total bleeding events was noted with the post-procedural addition of 
clopidogrel to aspirin-resistant patients (25% vs. 19%; RR: 1.34 [95% CI: 0.80 to 2.23]; two-tailed 
p=0.33, one-tailed p=0.17). A post-hoc analysis excluding patients requiring anticoagulation during 
the follow-up period was also performed. The incidence of bleeding events in the per-protocol analysis 
did not differ significantly from the intention-to-treat analysis (24% in the dAPT group vs. 19% in the 
aspirin monotherapy group; RR: 1.28 [95% CI: 0.75 to 2.20]; two-tailed p=0.39, one-tailed p=0.23). 
The incidence of the primary end-point was analyzed in patient subgroups, stratified according to the 
presence or absence of individual comorbidities or clinical characteristics. We found a statistically 
significant reduction in the frequency of MACCE in patients aged less than 65 years (0% vs. 10%, 
p=0.02). Analogously, patients with a body mass index (BMI) >30 kg/m
2
 were more likely to benefit 
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from platelet inhibition with clopidogrel on the background of aspirin therapy in the prevention of the 
composite adverse outcome.  The incidences of MACCE among obese patients were 0% with the 
dAPT strategy vs. 18% in the aspirin-only arm (p<0.01). The subgroup analyses are presented in Table 
4.  Dual antiplatelet therapy did not increase the incidence of bleeding events in patients younger than 
65 years (22% vs. 22%; RR: 0.99 [95% CI: 0.48 to 2.04]; two-tailed p=1.0, one-tailed p=0.61).  
Similarly, dAPT did not significantly increase bleeding among patients with a BMI>30 kg/m
2
 (29% 
vs. 20%; RR: 1.46 [95% CI: 0.69 to 3.11]; two-tailed p=0.45, one-tailed p=0.23). Similar bleeding 
rates were noted in all other studied subgroups (all one- and two-tailed p>0.05).  
 
DISCUSSION 
The principal goal of this trial was to measure the impact of enhanced platelet inhibition with 
clopidogrel on the background of standard therapy in aspirin-resistant CABG patients on the incidence 
of adverse events. This is the first prospective randomized study to address the clinical impact of 
augmented anti-platelet therapy after CABG in patients with aggregometry-documented aspirin 
resistance.  
Platelets are anuclear cell fragments harboring unique adhesion mechanisms that are as critical 
to arresting bleeding as they are to atherothrombosis.
19
 They are at a junction between inflammatory 
and thrombotic cascades, playing an active part in both of them.
19
 Suppressing platelet aggregability is 
an integral component in the management of coronary artery disease. The rationale for using 
clopidogrel in patients with a history of cardiac surgery has been validated in the Clopidogrel vs. 
Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study.
20
 The relative risk reduction of 29% in 
the incidence of vascular death, stroke, MI or rehospitalization in the CABG subgroup exceeded the 
benefit seen in the general CAPRIE study population.
20
 In the Clopidogrel in Unstable angina to 
prevent Recurrent Events (CURE) trial, clopidogrel proved superior to placebo in the prevention of 
MACCE.
21
 The degree of risk reduction with dAPT paralleled the patient complexity, with the greatest 
benefit seen in higher risk subgroups.
21
 The reduction in the frequency of MACCE with dAPT was 
also represented in the CABG subgroup (RR 0.89; 95% CI, 0.71 to 1.11).
22
 The composite end-point 
of death and recurrent MI was also seen less frequently in a cohort of MI patients revascularized with 
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CABG who were taking clopidogrel.
11
 Furthermore, graft patency was improved by the dAPT protocol 
in comparison to aspirin monotherapy.
3,23
  Gao et al randomized CABG patients to receive either 
aspirin only (n=124), or aspirin plus clopidogrel (n=125).
3
 Computed tomographic imaging revealed 
better SVG patency in the dual antiplatelet treatment arm.
3
 In a similar study design, Sun et al 
suggested that, in the total of 79 patients that completed angiographic follow-up, clopidogrel was 
superior to placebo in preventing radial artery graft failure.
23
 A caveat worth noting was that only a 
low maintenance aspirin dose was administered (81-100 mg) in the monotherapy arm in the latter 
trials,
3,23
 which has been found to incompletely inhibit TxA2 production after CABG.
24
 The impact of 
individual responsiveness to aspirin was not reported in these studies.
3,23
 The combination of 
clopidogrel and aspirin also resulted in superior clinical outcomes in patients undergoing off-pump 
coronary artery bypass surgery (OPCAB).
25
 The higher postoperative platelet responsiveness in 
OPCAB in comparison to conventional CABG patients, as determined by P-selectin expression, adds 
credibility to strategies intensifying platelet inhibition in this subpopulation.
26
 The potential 
advantages of dual antiplatelet inhibition notwithstanding, its benefits have not been generally 
demonstrable in all trials investigating its impact. In the Clopidogrel for High Atherothrombotic Risk 
and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial evaluating patients with 
stable cardiovascular disease dAPT was ineffective in reducing the composite endpoint of death, MI or 
stroke.
27
  
Our study differed from the aforementioned trials in that it specifically targeted the CABG 
subpopulation that retained high platelet aggregability despite aspirin therapy. We found that 51% of 
patients undergoing elective CABG had incomplete inhibition of platelet reactivity with aspirin. The 
utilized aggregometry-based algorithm for discriminating between aspirin responders and non-
responders had a distinct advantage in comparison to conventional coagulation tests. It used whole 
blood at the patient’s own temperature for analysis, thereby measuring platelet activity within their 
physiological milieu. Similar incidences of post-CABG aspirin resistance were previously reported.
6
 
Our study revealed multiple facets of postoperative hypercoagulability. We found that the surgical 
procedure elicited an increase in both fibrinogen levels and platelet reactivity. While there is data to 
suggest that aspirin resistance postoperatively is a transient phenomenon,
28
 this observed early 
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hypercoagulability may render the grafts particularly vulnerable during this period. The parallel and 
synergistic inhibitions of the COX-1 and ADP-mediated platelet activation pathways result in 
amplification of platelet inhibition,
5
 which we hypothesized to be potentially useful in patients 
exhibiting single anti-platelet drug resistance. Our trial, however, did not prove that the combination 
of aspirin and clopidogrel was superior in reducing the frequency of the primary endpoint to aspirin 
monotherapy in aspirin-resistant CABG patients. These results mirror the observations from a 
retrospective analysis of propensity-matched cohorts, which also found no survival benefit for dAPT 
over aspirin after CABG.
29
 Furthermore, one-year SVG intimal hyperplasia, as documented by 
intravascular ultrasound, in the Clopidogrel After Surgery for Coronary Artery DiseasE (CASCADE) 
study was not improved by dAPT (n=46) in comparison to an aspirin-only antiplatelet regime (n=44).
4
 
Our data did, however, suggest that patients younger than 65 years and those with a body mass index 
>30 kg/m
2
 might benefit from dual antiplatelet therapy in the setting of aspirin resistance. This gain 
was not offset by increasing bleeding events in neither the entire study cohort nor any of the 
subgroups. We believe that a study evaluating the potential of these aspirin-resistant subgroups to 
capitalize on enhancement of anti-platelet therapy is warranted.  
Our study has significant limitations. The estimation of the sample size required to test the null 
hypothesis was based on an exact binomial test power analysis.
18
 We cannot reliably exclude the 
possibility that the study may have been underpowered. In point of fact, a non-significant 39% relative 
risk reduction in the primary end-point was noted with the addition of clopidogrel to aspirin in the 
context of aspirin resistance. Our results may provide an impetus for the conduct of a larger scale 
study of a similar design. Another potential drawback of our study stems from the lack of an 
unequivocal definition of aspirin resistance. Aggregometry in our study revealed a continuum in 
individual platelet inhibition responses to aspirin. The cut-off points of multiple platelet function tests 
differentiating between aspirin response and resistance are based on definition, rather than 
unambiguous clinical data supporting their relevance. Furthermore, different laboratory pathway 
descriptors of platelet function yield varying incidences of high on-therapy residual platelet reactivity. 
One should, therefore, resist extrapolating results based on one platelet assessment instrument onto a 
larger group of platelet function tests, until confirmation of interchangeability has been established.  
 11
In conclusion, this prospective randomized trial showed that enhancing platelet inhibition with 
clopidogrel in aspirin-resistant patients after CABG did not result in a reduction of major adverse 
cardiac and cerebrovascular events. However, our subgroup analysis showed that obese patients and 
those younger than 65 years experience a statistically significant benefit from dAPT in the prevention 
of MACCE.  
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Figure 1. Patient eligibility, randomization and follow-up 
 
CABG = coronary artery bypass grafting; MI = myocardial infarction; dAPT = dual antiplatelet therapy; PCI = 
percutaneous coronary intervention; POD = postoperative day; PFT = platelet function testing; BARC = 
Bleeding Academic Research Consortium 
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Figure 2. Increases in ASPI test values in the aspirin-monotherapy (A) and Dual APT groups (B) in 
response to surgery. Changes in ADP test values in the aspirin-monotherapy (C) and Dual APT groups 
(D) in response to surgery. 
 
*Wilcoxon matched-pairs test 
APT = antiplatelet therapy; ASPI = cyclooxygenase dependent platelet aggregation; ADP = adenosine 
diphosphate; Preop = preoperative; POD = postoperative day; AUC = area under the curve 
 
 
 
 
 
 

Table 1. Baseline Demographic and Clinical Profiles (N=219) 
 
 
 
Variable 
Aspirin 
Monotherapy 
(n=107) 
Aspirin Plus 
Clopidogrel 
(n=112) 
p* 
Age (years) 65±9 65±8 0.69 
Male gender 82 (77%) 83 (74%) 0.75 
Body mass index (kg/m
2
) 30±4 29±4 0.21 
EuroSCORE 3.6±3.7 3.5±3.0 0.44 
LVEF (%) 55±10 53±10 0.16 
Hyperlipidemia
†
 103 (96%) 108 (96%) 1.00 
Diabetes mellitus 41 (38%) 43 (38%) 1.00 
Smoker 41 (38%) 38 (34%) 0.57 
Hypertension
‡
 103 (96%) 108 (96%) 1.00 
Left main narrowing 57 (53%) 48 (43%) 0.14 
Three-vessel coronary disease 80 (75%) 88 (79%) 0.53 
Preoperative platelet reactivity    
ASPI test values, AUC 38±28 35±30 0.27 
ADP test values, AUC 80±25 77±26 0.47 
Preoperative medications 
  
 
Clopidogrel 27 (25%) 37 (33%) 0.24 
Aspirin 94 (88%) 100 (89%) 0.83 
B-blocker 83 (78%) 101 (90%) 0.02 
Angiotensin-converting enzyme 
inhibitor 
67 (63%) 61 (54%) 0.27 
Statin 104 (97%) 108 (96%) 1.00 
 
 
* Two-tailed p 
†
 Hyperlipidemia was defined as any of the following: history of hypercholesterolemia (LDL-
cholesterol>3.4 mmol/l or total cholesterol>5.2 mmol/l), hypertriglyceridemia (>1.7 mmol/L), 
hyperchylomicronemia or use of lipid-lowering medications to achieve target lipid/lipoprotein values 
‡ 
Hypertension was defined as 2 or more systolic blood pressure (BP) measurements ≥140 mmHg or 
diastolic BP readings ≥90 mmHg, or use of anti-hypertensive medications to achieve the desired BP values 
in patients with a history of high BP 
 EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection 
fraction; ASPI=cyclooxygenase dependent platelet aggregation; AUC=area under the curve; 
ADP=adenosine diphosphate 
  
Table 2. Perioperative Details and Postoperative Medication Use 
 
 
 
 
Aspirin 
Monotherapy 
(n=107) 
Aspirin Plus 
Clopidogrel 
(n=112) 
p* 
Perioperative Data 
  
 
Left internal mammary use 101 (94%) 104 (93%) 0.78 
Cross-clamp time (min) 57±22 59±22 0.45 
CPB time (min) 86±25 87±28 0.62 
Postoperative AF 27 (25%) 36 (32%) 0.30 
Postoperative inotrope use 31 (29%) 36 (32%) 0.66 
Postoperative Platelet Reactivity    
ASPI test values, AUC 53±22 60±29 0.19 
ADP test values, AUC 97±31 95±34 0.89 
Postoperative Medications 
  
 
Clopidogrel 0  112 (100%) <0.01 
Aspirin 107 (100%) 112 (100%) 1.00 
Beta blocker 101 (94%) 101 (90%) 0.31 
Angiotensin-converting enzyme 
inhibitor 
12 (11%) 17 (15%) 0.43 
Statin 100 (93%) 104 (93%) 1.00 
 
 
*Two-tailed p 
CPB=cardiopulmonary bypass; AF=atrial fibrillation; ASPI=cyclooxygenase dependent platelet 
aggregation; ADP=adenosine diphosphate; AUC=area under the curve  
 
 
 
Table 3. Primary and Secondary Study Outcomes (Intention-to-Treat Analysis) 
 
 
 
Aspirin 
Monotherapy 
Aspirin Plus 
Clopidogrel 
Relative Risk 
(95% CI) 
p* 
Efficacy End-points (n=107 ) (n=112)   
MACCE  11 (10%) 7 (6%) 0.61 (0.25-1.51) 0.33 
All-cause death  4 (4%) 2 (2%) 0.48 (0.09-2.55) 0.44 
Cardiovascular death 1 (1%) 1 (1%) 0.96 (0.06-15.08) 1.00 
Stroke  4 (4%) 1 (1%) 0.24 (0.03-2.10) 0.20 
Non-fatal MI  1 (1%) 1 (1%) 0.96 (0.06-15.08) 1.00 
Composite MI or stroke 
or cardiovascular death  
5 (5%) 3 (3%) 0.57 (0.14-2.34) 0.49 
Cardiovascular 
hospitalization 
3 (3%) 3 (3%) 0.96 (0.20-4.63) 1.00 
Safety End-points     
Total bleeding events 20 (19%) 28 (25%) 1.34 (0.80-2.23) 0.33 
BARC 1 19 (18%) 23 (21%) 1.16 (0.67-2.00) 0.61 
BARC 2 0  1 (1%) N/A 1.00 
BARC 3 1 (1%) 4 (4%) 3.82 (0.43-33.65) 0.37 
BARC 4 0  0 N/A 1.00 
BARC 5 0  0 N/A 1.00 
 
 
*Two-tailed p 
CI=confidence intervals; MACCE=major adverse cardiac and cerebrovascular events; MI=myocardial 
infarction; BARC=Bleeding Academic Research Consortium 
 
Table 4. Subgroup Analyses of the Primary End-Point 
 
 
 
 
Aspirin 
Monotherapy 
Aspirin Plus 
Clopidogrel 
Relative Risk 
(95% CI) 
p* 
Age, y     
≥65 6/58 (10%) 7/58 (12%) 1.17 (0.42-3.26) 1.00 
<65 5/49 (10%) 0/54  N/A 0.02 
Sex     
Male 7/82 (9%) 6/83 (7%) 0.85 (0.30-2.41) 0.78 
Female 4/25 (16%) 1/29 (3%) 0.22 (0.03-1.81) 0.17 
Body mass index, 
kg/m
2
 
    
>30 8/45 (18%) 0/41  N/A <0.01 
≤30 3/62 (5%) 7/71 (10%) 2.04 (0.55-7.54) 0.34 
EuroSCORE     
≥3 6/48 (13%) 5/48 (10%) 0.83 (0.27-2.55) 1.0 
<3 5/59 (8%) 2/64 (3%) 0.37 (0.07-1.83) 0.26 
LVEF     
>50% 5/66 (8%) 4/63 (6%) 0.84 (0.24-2.98) 1.0 
≤50% 6/41 (15%) 3/49 (6%) 0.42 (0.11-1.57) 0.29 
Diabetes mellitus     
Yes 7/41 (17%) 3/43 (7%) 0.41 (0.11-1.47) 0.19 
No 4/66 (6%) 4/69 (6%) 0.96 (0.25-3.67) 1.0 
Three vessel disease     
Yes 8/80 (10%) 6/88 (7%) 0.68 (0.25-1.88) 0.58 
No 3/27 (11%) 1/24 (4%) 0.38 (0.04-3.37) 0.61 
Left main disease     
Yes 8/57 (14%) 2/48 (4%) 0.30 (0.07-1.33) 0.11 
No 3/50 (6%) 5/64 (8%) 1.30 (0.33-5.19) 1.0 
 
 
*Two-tailed p 
CI=confidence interval; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left 
ventricular ejection fraction 
 
